Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS)
CNY 51.9
(0.31%)
CNY 51.9
(0.31%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 353.11 Million | 29.29 Million | 180.74 Million | 141.38 Million | 46.13 Million | 96.05 Million |
| Net Income | 162.93 Million | 122.77 Million | 108.8 Million | 120.02 Million | 44.8 Million | 44.68 Million |
| Depreciation & Amortization | 140.15 Million | 99.96 Million | 84.76 Million | 70.7 Million | 41.62 Million | 23.91 Million |
| Deferred income taxes | -13.56 Million | -4.86 Million | 9.13 Million | 3.95 Million | -4.43 Million | -28.75 Million |
| Stock-based compensation | 22.28 Million | 460.8 Thousand | 5.78 Million | 6.48 Million | 6.69 Million | 447 Thousand |
| Change in working capital | -5.38 Million | -203.3 Million | -48.55 Million | -81.53 Million | -66.56 Million | 13.21 Million |
| Other non-cash items | 377.97 Million | 8.15 Million | 20.8 Million | 21.74 Million | 24 Million | 14.25 Million |
| Investing Cash Flow | -665.11 Million | -449.74 Million | -236.93 Million | -163.17 Million | -275.71 Million | -210.3 Million |
| Investments in PPE | -660.63 Million | -438.36 Million | -233.35 Million | -111.28 Million | -276.38 Million | -197.48 Million |
| Acquisitions | 2.37 Million | 13.11 Million | 339.93 Thousand | 16.99 Million | 276.62 Million | -13.78 Million |
| Investment purchases | -556.5 Million | -724.95 Million | -914 Million | -176 Million | -86 Million | -436 Million |
| Sales/Maturities of investments | 549.65 Million | 700.39 Million | 910.08 Million | 95.65 Million | 86.43 Million | 436.78 Million |
| Other Investing Activities | -1.56 Million | 56.18 Thousand | 1.64 | 11.45 Million | -276.38 Million | 171.39 Thousand |
| Financing Cash Flow | 631.89 Million | 236.91 Million | 534.89 Million | 39.5 Million | 98.59 Million | 284.48 Million |
| Debt repayment | -696.29 Million | -128.07 Million | -422.79 Million | -239.24 Million | -156.99 Million | -183.95 Million |
| Dividends payments | -42.63 Million | -31.97 Million | -6.04 Million | -11.63 Million | -4.47 Million | -8.38 Million |
| Common Stock Repurchased | - | - | -762.62 Million | - | - | - |
| Common Stock Issuance | - | - | 762.62 Million | - | - | - |
| Other Financing Activities | 1.37 Billion | 405.55 Million | 963.72 Million | 290.38 Million | 266.49 Million | 476.82 Million |
| Accounts receivables | -126.48 Million | -145.03 Million | -45.87 Million | -42.31 Million | -33.61 Million | 39.97 Million |
| Accounts payables | 180.38 Million | 58.33 Million | 75.81 Million | 30.25 Million | -7.84 Million | 19.86 Million |
| Inventory | -82.58 Million | -111.73 Million | -87.62 Million | -73.43 Million | -20.67 Million | -17.86 Million |
| Other working capital | 23.3 Million | -4.86 Million | 9.13 Million | 3.95 Million | -4.43 Million | 31.08 Million |
| Cash at beginning of period | 399.96 Million | 545.19 Million | 68.07 Million | 58.09 Million | 189.21 Million | 19.44 Million |
| Cash at end of period | 749.08 Million | 360.84 Million | 545.19 Million | 68.07 Million | 58.09 Million | 189.21 Million |
| Capital Expenditure | -660.63 Million | -438.36 Million | -233.35 Million | -111.28 Million | -276.38 Million | -197.48 Million |
| Effect of forex changes on cash | -3.21 Million | -816.16 Thousand | -1.57 Million | -7.73 Million | -132.99 Thousand | -464.02 Thousand |
| Net cash flow / Change in cash | 349.11 Million | -184.35 Million | 477.12 Million | 9.97 Million | -131.11 Million | 169.77 Million |
| Free Cash Flow | -307.52 Million | -409.07 Million | -52.6 Million | 30.09 Million | -230.25 Million | -101.42 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 123.08 Million | 160.83 Million | 66.32 Million | 71.22 Million | 162.93 Million | 49.86 Million |
| Depreciation & Amortization | - | 50.33 Million | 50.33 Million | 35.81 Million | 140.15 Million | -65.44 Million |
| Deferred income taxes | - | - | - | 163.47 Million | -13.56 Million | - |
| Stock-based compensation | - | 23.84 Million | - | 22.28 Million | 22.28 Million | - |
| Change in working capital | - | -232.76 Million | - | -185.76 Million | -5.38 Million | -14.95 Million |
| Other non-cash items | -53.62 Million | 9.8 Million | 12.39 Million | 173.46 Million | 377.97 Million | 92.93 Million |
| Investing Cash Flow | -288.59 Million | -145.05 Million | -407.2 Million | -185.51 Million | -665.11 Million | -262.38 Million |
| Investments in PPE | -322.09 Million | -160.92 Million | -167.22 Million | -226.62 Million | -660.63 Million | -186.52 Million |
| Acquisitions | 413 Thousand | 868.1 Thousand | 19.84 Thousand | 2.2 Million | 2.37 Million | -893.97 Thousand |
| Investment purchases | -432.5 Million | -500 Million | -500 Million | -45 Million | -556.5 Million | -196.45 Million |
| Sales/Maturities of investments | 465.58 Million | 515 Million | 260 Million | 83.9 Million | 549.65 Million | 121.49 Million |
| Other Investing Activities | 413 Thousand | 868.1 Thousand | -239.73 Million | 43.09 Million | -1.56 Million | -0.31 |
| Financing Cash Flow | 224.44 Million | 64.71 Million | 148.48 Million | 518.91 Million | 631.89 Million | 58.54 Million |
| Debt repayment | -255.33 Million | -135.45 Million | -155.74 Million | -97.85 Million | -696.29 Million | -75.35 Million |
| Dividends payments | -29.42 Million | -91.23 Million | -5.45 Million | -42.63 Million | -42.63 Million | -3.36 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.46 Million | -67.32 Million | -7.26 Million | 659.41 Million | 1.37 Billion | 137.25 Million |
| Accounts receivables | - | -207.04 Million | - | -126.48 Million | -126.48 Million | -38.96 Million |
| Accounts payables | - | - | - | - | 180.38 Million | 342.69 Thousand |
| Inventory | - | -51.56 Million | - | -82.58 Million | -82.58 Million | 24 Million |
| Other working capital | - | 25.83 Million | - | 23.3 Million | 23.3 Million | -342.69 Thousand |
| Cash at beginning of period | 540.76 Million | 544.17 Million | 749.08 Million | 299.19 Million | 399.96 Million | 371.06 Million |
| Cash at end of period | 543.61 Million | 555.21 Million | 544.17 Million | 749.08 Million | 749.08 Million | 228.76 Million |
| Capital Expenditure | -322.09 Million | -160.92 Million | -167.22 Million | -226.62 Million | -660.63 Million | -186.52 Million |
| Effect of forex changes on cash | -1.86 Million | 2.28 Million | 986.03 Thousand | -1.67 Million | -3.21 Million | -853.51 Thousand |
| Net cash flow / Change in cash | 2.85 Million | 11.03 Million | -204.9 Million | 449.88 Million | 349.11 Million | -142.3 Million |
| Free Cash Flow | -252.63 Million | -40.62 Million | -88.5 Million | -109.58 Million | -307.52 Million | -124.13 Million |
601326
BEDMUTHA
SIEB
SSR
6615
600521